AC Immune (ACIU) Shares Outstanding (Weighted Average) (2014 - 2026)

AC Immune (ACIU) has 13 years of Shares Outstanding (Weighted Average) data on file, last reported at $616.0 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $616.0 million, up 15.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $616.0 million (up 15.61% YoY), and the FY2025 annual result was $581.2 million, up 6.4% from the prior year.
• Shares Outstanding (Weighted Average) rose to $616.0 million in Q1 2026 per ACIU's latest filing, from $602.9 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $2.4 billion in Q2 2024 and troughed at $86.7 million in Q4 2022.
• A 5-year average of $671.8 million and a median of $544.5 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Weighted Average) soared 472.08% in 2024, then plunged 76.31% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $86.7 million in 2022, then gained by 10.09% to $95.5 million in 2023, then surged by 472.08% to $546.2 million in 2024, then climbed by 10.37% to $602.9 million in 2025, then grew by 2.17% to $616.0 million in 2026.
• Business Quant data shows ACIU's Shares Outstanding (Weighted Average) at $616.0 million in Q1 2026, $602.9 million in Q4 2025, and $600.3 million in Q3 2025.